Home › Funds › Candriam S.C.A. › BIIB
Candriam S.C.A. position in BIIB
BIOGEN INC · Health Care
Candriam S.C.A. reported holding 412,472 shares of BIIB (BIOGEN INC) in its Q3 2026 13F filing — a position valued at US$93.5M, representing 0.42% of its reported portfolio and ranking #45 among its reported holdings. Candriam S.C.A. has disclosed BIIB holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Candriam S.C.A.'s BIIB position evolved
Candriam S.C.A. first disclosed a stake in BIIB in Q3 2023 at 233,959 shares (US$60.1M). The position peaked in Q3 2026 at 412,472 shares, worth US$93.5M. Across 13 filings, Candriam S.C.A. increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 412,472 shares valued at US$93.5M — an increase of 28,146 shares quarter over quarter.. Notable position changes include a 44% increase in Q1 2024 (shares rose 8% over the following quarter), a 108% increase in Q4 2025 (shares rose 4% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 233.96K | $60.13M | New |
| Q4 2023 | 185.28K | $47.95M | Reduce |
| Q1 2024 | 267.04K | $57.58M | Add |
| Q2 2024 | 266.46K | $61.77M | Hold |
| Q3 2024 | 212.46K | $41.18M | Reduce |
| Q4 2024 | 201.96K | $30.88M | Reduce |
| Q1 2025 | 186.78K | $25.56M | Reduce |
| Q2 2025 | 163.31K | $20.51M | Reduce |
| Q3 2025 | 158.82K | $22.25M | Reduce |
| Q4 2025 | 330.47K | $58.16M | Add |
| Q1 2026 | 381.77K | $69.99M | Add |
| Q2 2026 | 384.33K | $82.96M | Add |
| Q3 2026 | 412.47K | $93.51M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BIIB and 13F data
BIIB (BIOGEN INC) is a Health Care company. 20 other funds we track also report a position in BIIB — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$3.43B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BIIB
- PRIMECAP MANAGEMENT CO/CA/ 15.20M sh · $3.43B · Q3 2026
More on Candriam S.C.A.
FAQ
How long has Candriam S.C.A. held BIIB?
Candriam S.C.A. has disclosed BIIB holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Candriam S.C.A.'s current position in BIIB?
As of Q3 2026, Candriam S.C.A. holds 412.47K shares of BIIB (BIOGEN INC), valued at $93.51M, representing 0.42% of its reported portfolio and ranking #45.
Has Candriam S.C.A. been buying or selling BIIB?
In the latest 13F filing (Q3 2026), Candriam S.C.A. increased its position in BIIB. The position peaked in Q3 2026 at 412.47K shares.
Which other funds hold BIIB?
Other major institutional holders of BIIB include PRIMECAP MANAGEMENT CO/CA/, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.